|
Volumn 69, Issue 10, 2015, Pages 594-596
|
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
a b c d e f g h i j k l l l l l l m
h
Evangelisches
(Germany)
|
Author keywords
[No Author keywords available]
|
Indexed keywords
OLAPARIB;
PLACEBO;
PLATINUM DERIVATIVE;
CANCER CHEMOTHERAPY;
CANCER FATIGUE;
CANCER PATIENT;
CANCER RECURRENCE;
CANCER SURVIVAL;
CHEMOSENSITIVITY;
CHEMOTHERAPY INDUCED ANEMIA;
CONTROLLED STUDY;
DRUG SENSITIVITY;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
FEMALE;
GENE DELETION;
GENE MUTATION;
HUMAN;
INTERACTIVE VOICE RESPONSE SYSTEM;
MAINTENANCE CHEMOTHERAPY;
MAJOR CLINICAL STUDY;
MULTIPLE CYCLE TREATMENT;
NOTE;
OVARY CANCER;
OVERALL SURVIVAL;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PROGRESSION FREE SURVIVAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RETROSPECTIVE STUDY;
SECONDARY ANALYSIS;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
TUMOR SUPPRESSOR GENE;
WILD TYPE;
|
EID: 84925853373
PISSN: 00297828
EISSN: 15339866
Source Type: Journal
DOI: 10.1097/ogx.0000000000000107 Document Type: Note |
Times cited : (12)
|
References (0)
|